文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

掌跖脓疱病的真实世界证据:患者特征、诊断挑战与治疗生存预测因素

Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study.
PubMed 文献 · Br J Dermatol · 2026-01-01

本研究基于奥地利银屑病登记库(PsoRA)1997年至2024年的数据,回顾性分析190例掌跖脓疱病(PPP)患者的397次治疗。乌司奴单抗的中位治疗生存时间最长(2.7年),但IL-23p19抑制剂引入后其优势消失。传统系统治疗和光疗的停药风险显著高于生物制剂。

要点

  • 超过半数PPP患者初诊被误诊为湿疹,平均延迟2.8年。
  • 乌司奴单抗治疗生存最长(2.7年),但IL-23p19抑制剂上市后优势消失。
  • 传统系统治疗和光疗的停药风险显著高于生物制剂。

核心结论

  • 超过半数PPP患者因初诊误诊而经历数年诊断延迟。
  • 乌司奴单抗治疗生存最长,但IL-23p19抑制剂引入后其优势消失。
  • 较短病程和合并斑块状银屑病是治疗停药的普遍风险因素。
  • 合并症和银屑病关节炎是停用生物制剂的风险因素。

研究设计与样本

  • 回顾性研究,使用奥地利银屑病登记库(PsoRA)1997年5月16日至2024年4月11日的数据。
  • 纳入190例PPP患者,共397次治疗。

主要发现

  • 患者以女性为主(141/190;74.2%),吸烟者占78%(76/98)。
  • 治疗分布:生物制剂49.9%(198/397)、光疗25.2%(100/397)、传统系统治疗24.9%(99/397)。
  • 所有治疗的中位生存时间为0.6年(95%CI 0.5-0.8),乌司奴单抗最长2.7年(95%CI 2.3-上限未达到)。
  • 与传统系统治疗(HR 2.17;P<0.001)和光疗(HR 4.43;P<0.001)相比,生物制剂的停药风险显著更低。

关键数值与推荐

  • 病程≥2至<10年(HR 0.66;P=0.05)和≥10年(HR 0.59;P=0.004)显著降低停药风险。
  • 合并斑块状银屑病显著增加停药风险(HR 1.43;P=0.05)。
  • 在生物制剂队列中,合并关节炎(HR 2.11;P=0.002)和一种合并症(HR 2.34;P=0.03)增加停药风险。
  • 性别、发病年龄和吸烟不影响停药风险。

临床怎么用

  • PPP患者应警惕湿疹误诊,早期识别可减少诊断延迟。
  • 生物制剂治疗生存优于传统系统治疗和光疗,乌司奴单抗曾显示最长生存。
  • 合并斑块状银屑病、关节炎或合并症者需关注停药风险。

局限性

  • 回顾性登记研究设计可能存在数据缺失和选择偏倚。
  • 部分分析样本量较小(如误诊分析n=69,吸烟分析n=98)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the clinical characteristics, diagnostic delay and treatment survival in patients with palmoplantar pustulosis (PPP). OBJECTIVES: To analyse the survival rates of patients with PPP in Austria treated with phototherapy, conventional systemic therapies and biologics. METHODS: This was a retrospective study using data from the Psoriasis Registry Austria (PsoRA). The analysis included data collected between 16 May 1997 and 11 April 2024 from patients with PPP. RESULTS: We included data from 190 patients who underwent 397 treatments. Fifty-four per cent of patients (n = 37/69) were initially misdiagnosed as having eczema with a mean (SD) diagnostic delay of 2.8 (4.8) years. Patients were predominantly women (n = 141/190; 74.2%) and smoked (n = 76/98; 78%). Patients were treated with biologics (n = 198/397; 49.9%), phototherapy (n = 100/397; 25.2%) and conventional systemic therapies (n = 99/397; 24.9%). Median survival time for all treatments was 0.6 years [95% confidence interval (CI) 0.5-0.8], with patients on ustekinumab having the longest median survival time of 2.7 years (95% CI 2.3-upper limit not reached), surpassing all other therapies. This superiority disappeared after interleukin (IL)-23p19 inhibitors were introduced in Austria. Compared with biologics, conventional systemic treatments [hazard ratio (HR) 2.17; P < 0.001] and phototherapy (HR 4.43; P < 0.001) were associated with a significantly higher risk of treatment discontinuation. In the overall cohort, disease durations of ≥ 2 to < 10 years (HR 0.66; P = 0.05) and ≥ 10 years (HR 0.59; P = 0.004) significantly reduced the risk of treatment discontinuation, while concomitant plaque psoriasis significantly increased the risk of treatment discontinuation (HR 1.43; P = 0.05). In the biologic cohort, concomitant arthritis (HR 2.11; P = 0.002) and the presence of one comorbid disease (HR 2.34; P = 0.03) increased the risk of treatment discontinuation. Furthermore, sex, age at disease onset and smoking did not influence the risk of treatment discontinuation. CONCLUSIONS: Our findings suggest that more than half of patients with PPP experience a diagnostic delay of several years due to an initial misdiagnosis. Patients on ustekinumab (IL-12/23p40 inhibitor) had the longest treatment survival, although its superiority diminished with the introduction of IL-23p19 inhibitors. Finally, shorter disease duration and concomitant plaque psoriasis is a general risk factor for treatment discontinuation, while the presence of a comorbidity and concomitant psoriatic arthritis are risk factors for discontinuing biologics. Palmoplantar pustulosis is a rare skin disease of the palms of the hands and soles of the feet. The disease affects people’s quality of life. Patients with the disease often have many other conditions. We wanted to find out how patients with the disease in Austria are diagnosed and treated. Using a database called the ‘Psoriasis Registry Austria’, we found 190 patients with the disease. These 190 patients were treated with 397 different therapies. Over half of patients were initially misdiagnosed with eczema. This led to an average delay of about 3 years before patients received the correct diagnosis. Most patients were women and most smoked. The most common treatment was with medications called ‘biologics’. These target specific inflammatory molecules. Patients stayed on treatment with a biologic called ustekinumab for the longest amount of time. Patients were more likely to stop other types of medication and light therapy earlier than if they were taking biologics. Psoriasis and not having had the disease for a long time increased the risk of patients stopping treatment. Age, patient sex and smoking did not affect treatment duration. Many patients with palmoplantar pustulosis have a long wait before they are diagnosed correctly. Despite advances in therapies, the disease remains difficult to treat. A drug called ustekinumab showed the best long-term treatment survival.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Graier T, Bordag N, Weger W, et al. Real-world evidence on palmoplantar pustulosis: patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study. Br J Dermatol. 2026. PMID: 41077554. doi:10.1093/bjd/ljaf394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。